ClearPoint Neuro Announces Third Quarter 2026 Results on October 28

SOLANA BEACH, Calif., October 14, 2026 /CourierPR/ -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) will release its financial results for the third quarter of 2026 on October 28, 2026, after the market close. The company will host a live broadcast review of its third-quarter performance at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on the same day. Investors and analysts are invited to participate in the conference call, which can be accessed by dialing (877) 407-9034 or (201) 493-6737 for international callers. The conference ID is 413671.

For those unable to join the live broadcast, a replay will be available from November 27, 2026, onwards. The replay can be accessed by calling (877) 660-6853 or (201) 612-7415, with the same conference ID. An online archive of the broadcast will also be available on the company’s investor website at ir.clearpointneuro.com.

ClearPoint Neuro is a global device, cell, and gene therapy-enabling company that offers precise navigation to the brain and spine. The company provides both established clinical products and pre-clinical development services for controlled drug and device delivery. Its flagship product, the ClearPoint Neuro Navigation System, has received FDA clearance and CE-marking. ClearPoint Neuro collaborates with healthcare and research centers across North America, Europe, Asia, and South America, as well as with leading pharmaceutical and biotech companies, academic centers, and contract research organizations.

The company’s forward-looking statements, which include expectations for revenues, operating expenses, and the adequacy of cash and cash equivalent balances, are subject to various risks and uncertainties. These include the market acceptance of its products, regulatory requirements, and the continued use of its products by its biotech partners. ClearPoint Neuro’s ability to maintain its relationships with biotech partners and to enter into new partnerships is also crucial to its success.

ClearPoint Neuro is engaged in the development and commercialization of innovative solutions for the delivery of therapeutic agents to the central nervous system. The company’s services include the provision of clinical specialist support and technical expertise to its partners, enabling them to conduct pre-clinical and clinical trials. To date, thousands of procedures have been performed and supported by the company’s field-based clinical specialist team, which offers support and services to its customers and partners worldwide.

The company’s financial results will provide insights into its performance, including revenue, expenses, and cash flow. Investors and analysts will have the opportunity to hear from the company’s management team, who will discuss the company’s strategic initiatives and future outlook. The live broadcast will be available for listening, and a detailed transcript and recording will be made available on the company’s investor relations website.